Date:3/10/2010

oney">$0.5 million for the quarter ended December 31, 2009, or $0.09 per share on a basic and fully diluted basis, compared to a net income of $5.2 million or $0.87 per share basic and $0.75 per share on a fully diluted basis, for the same period in 2008. For the full year ended December 31, 2009, the Company reported a net loss of $2.0 million, or $0.32 per share on a basic and fully diluted basis, compared to a net income of $3.7 million, or $0.64 per share basic and $0.55 per share on a fully diluted basis for 2008.

Revenue for the fourth quarter of 2009 was $0.8 million, compared to $7.2 million for the same period in 2008. For the full year ended December 31, 2009, revenue was $3.2 million, compared to $8.4 million in 2008. The decrease in revenue in the 2009 period was mainly due to a sublicense fee of $6.4 million recognized in the fourth quarter of 2008.

Research and development expenses for the fourth quarter of 2009 were $0.1 million, compared to $0.2 million for the same pe
'/>"/>

SOURCE BioSpecifics Technologies Corp. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
2. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
3. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
4. BioSpecifics Technologies Corp. Announces FDA Approval of XIAFLEX(TM) for Treatment of Dupuytrens Contracture
5. BioSpecifics Technologies Corp. to Present at the Piper Jaffray 21st Annual Health Care Conference
6. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
7. BioSpecifics Technologies Corp. to Present at Cowen and Company 30th Annual Health Care Conference
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2009 Financial Results on March 10, 2010
9. BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytrens Contracture
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction